Azenta has been Selected by the Crohn's & Colitis
Foundation as its Sample Management Services Provider for its
Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical
Registries
BURLINGTON, Mass., June 4, 2024
/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has
been selected by the Crohn's & Colitis Foundation (the
"Foundation") as its sample management services provider for two of
its large-scale prospective research cohorts, CAPTURE IBD and IBD
SIRQC, which investigate pediatric and surgical care for Crohn's
disease and ulcerative colitis. Azenta will provide sample
management services, including sample processing, analysis,
logistics, and storage for these pivotal studies.
These studies are part of the Foundation's IBD
Plexus® research ecosystem and data platform that
redefines how the research community studies Crohn's disease and
ulcerative colitis to advance next-generation discoveries and novel
therapies. The platform offers a rich research ecosystem for
academic and life science researchers, providing prospective,
longitudinal, and well-phenotyped data linked to biosamples to
accelerate answering high-impact, patient-prioritized questions,
and drive a revolutionary approach toward faster cures.
CAPTURE IBD (Cohort for Pediatric Translational and Clinical
Research in Inflammatory Bowel Disease) is a multi-center,
longitudinal study designed to advance precision medicine in
pediatric IBD. CAPTURE is looking to enroll several thousand
pediatric patients at 12 participating sites in the United States.
IBD SIRQC (Surgical Innovation, Research, and Quality
Collaborative) is the Foundation's first-ever surgical research
initiative designed as a longitudinal surgical cohort that will
track long-term surgery outcomes including post-procedure
complications and disease recurrence. SIRQC is looking to enroll
5,000 patients at 9 participating sites in the United States.
"The integration of novel pediatric and surgical data and
biosamples into the IBD Plexus platform is critical to advance
understanding of the complexity of IBD and develop precision
medicine strategies," said Angela
Dobes, Senior Vice President, IBD Plexus, Crohn's &
Colitis Foundation. "We selected Azenta to support our CAPTURE and
SIRQC research initiatives because of their high-quality,
centralized sample management services and strong customer support.
We look forward to continuing the partnership."
"Azenta is delighted to be expanding our relationship with the
Crohn's & Colitis Foundation by supporting these critical
studies that have the potential to accelerate breakthroughs for the
Crohn's and ulcerative colitis community," said Kathi Shea, Vice President and General Manager
of Sample and Repository Services at Azenta. "Our support of the
Foundation goes back many years supporting clinical trial samples
using our core storage and GENEWIZ Multiomics & Synthesis
Solutions. We are proud to have been selected to support this
prestigious organization."
About Crohn's &Colitis Foundation
The Crohn's & Colitis Foundation is the leading nonprofit
organization focused on both research and patient support for
inflammatory bowel disease (IBD), with the mission of curing
Crohn's disease and ulcerative colitis and improving the quality of
life for the millions of Americans living with IBD. The
Foundation's work is dramatically accelerating the research
process, while also providing extensive educational and support
resources for patients and their families, medical professionals,
and the public.
To learn more about the IBD Plexus® program, visit
https://www.crohnscolitisfoundation.org/research/plexus
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington, Massachusetts, with operations in North
America, Europe and Asia. For more information,
please visit www.azenta.com.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
Azenta's use of third-party trademarks and brands are for
identification only and does not imply affiliation or
endorsement. All trademarks used herein are the property of
their respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-collaboration-with-the-crohns--colitis-foundation-to-support-its-crohns-disease-and-ulcerative-colitis-clinical-research-302163828.html
SOURCE Azenta